Chronic recordings from micromachined neural electrode arrays often fail a few weeks after implantation primarily due to the formation of an astro-glial sheath around the implant. We propose a drug delivery system, from conducting polymer (CP) coatings on the electrode sites, to modulate the inflammatory implant-host tissue reaction. In this study, polypyrrole (PPy) based coatings for electrically controlled and local delivery of the ionic form of an anti-inflammatory drug, dexamethasone (Dex), was investigated. The drug was incorporated in PPy via electropolymerization of pyrrole and released in PBS using cyclic voltammetry (CV). FTIR analysis of the surface showed the presence of Dex and polypyrrole on the coated electrode. The thickness of the coated film was estimated to be ~50 nm by ellipsometry. We were able to release 0.5 µg/cm 2 Dex in 1 CV cycle and upto 92% Dex after 30 CV cycles. In-vitro studies and immunocytochemistry on murine glial cells suggest that the released drug lowers the count of reactive astrocytes to the same extent as the added drug. In addition, the released drug is not toxic to neurons as seen by healthy neuronal viability in the released drug treated cells.
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INTRODUCTION
Neural prostheses are implantable microelectronic devices used to bypass, repair or restore damaged neurological function by electrical stimulation or recording from the peripheral and central nervous systems. The chronic application of these devices has been limited by their unpredictable failure over extended periods. Although the precise mechanism for this failure is not completely known, it is suggested that an undesirable brain tissue reaction to the device leads to the formation of a glial scar which then serves as a barrier to neural signal transduction [1] [2] [3] [4] [5] [6] [7] [8] .
Biomaterials strategies are being explored to minimize or eliminate the undesired tissue reaction. Two major directions are being taken, one being enhancing neuronal growth and adherence to the electrodes via immobilization of biomolecules on electrode surface or through release of growth factors or chemo-attractants from the electrodes [9] [10] [11] [12] [13] [14] [15] [16] [17] , and the other being mitigating the brain microenvironment through delivery of anti-inflammatory factors in the vicinity of the implant. Dexamethasone (Dex) is a synthetic glucocorticoid anti-inflammatory drug which can reduce inflammation in the Central Nervous System (CNS). The drug is believed to act through its glucocorticoid receptors found in most neurons and glial cells throughout the brain [18] . These receptors' pathways are involved in the inhibition of astrocyte proliferation [19] and microglial activation [20] . Additionally, as an anti-inflammatory substance, Dex reduces numerous pro-inflammatory cytokines, including IL-1β, IL-6, INF-γ and TNF-α [21] . Peripheral injections of Dex have been shown to effectively minimize the reactive tissue response to neural implants in the rat [22] . However, systemic injections have the obvious disadvantage of exposing the whole body to high dosages of the drug and its potential toxicity.
Local delivery of drugs at the implant/tissue interface would be most effective. Dexamethasone eluting coatings are being developed [23, 24] . The release of Dex from these coatings, indeed, decreased the degree of reactive tissue response of the brain implants as shown in immunohistopathological studies. However these passive drug eluting coatings can not last as long as needed in applications such as cortical prostheses nor can they release appropriate doses in response to the dynamic change of the local biochemical environment. A microfluidics-based drug injection system is also being investigated for the same purpose, wherein intracortical probes with microfluidic channels are fabricated and tested to understand the possibility of using diffusion-mediated delivery to deliver therapeutic agents into the immediate surroundings of the implanted devices [25] . Convective delivery is also plausible and this method can theoretically incorporate components such as pumps and valves for active control of the release. However, the current fabrication technology has not demonstrated the precision needed for sub-picoliter delivery. Furthermore, adding more components to the neural electrode arrays means more processing steps, more failure points and less reliability.
Conducting polymers have the ability to undergo reversible red-ox reaction under the stimulus of an electrical potential. The doped polymer film can be electrically switched between the oxidized state and reduced state [26] . The red-ox reaction involves charging and discharging of the polymer and is also accompanied by the movement of hydrated ions in and out of the bulk.
Utilizing this feature, efforts have been made to develop delivery systems in which conducting polymers can be loaded with some chemical substances (drug, growth factors) and the loaded dopants can be released in response to electrical stimulus. The anionic drugs salicylaten, 2-ethylhexylphosphate (EHP) and naproxen and the cationic drug dopamine have been incorporated into conducting polymer membrane and released by electrical potential stimulus in a controlled way [27] [28] [29] . Adenosine triphosphate (ATP) was shown to be released from polypyrrole upon sensing bioactive molecules in the solution [30] .
Polypyrrole and its derivatives are the most widely used conducting polymers in biomedical applications due to their biocompatibility and customizability [31] [32] [33] [34] [35] [36] . Polypyrrole has been electrically deposited onto the electrode site of the neural recording arrays together with CDPGYIGSR, a peptide fragment from laminin [9, 37] , to improve the neuron-electrode connection in vivo.
In the current study, polypyrrole (PPy) based electrode coating for controlled and local delivery of the ionic form of an anti-inflammatory drug, dexamethasone (Dex), was investigated.
The drug incorporation was done using a one-step electropolymerization. The release of the drug was carried out using cyclic voltammetric stimulus and was found to be precisely controllable i.e. the released amount was linear to the number of applied stimuli. The released dexamethasone showed anti-inflammatory effects by lowering number of reactive astrocytes in vitro. In primary neuronal culture, healthy neuronal growth was observed in the drug treated cultures, indicating that the delivery mechanism does not produce any toxic leachables and that the drug does not damage neurons at this dosage.
INCORPORATION OF DEX IN PPY-DEX FILMS ON GOLD ELECTRODES
INTRODUCTION
The first sets of experiments were conducted to incorporate the drug in the polymer films on the model gold electrodes. Gold coated coverslips were prepared and PPy-Dex films were deposited using one step electropolymerization. Upon deposition the films were analyzed using Fourier Transform Infrared Spectroscopy (FTIR), Ellipsometry and Atomic Force Microscopy (AFM).
Details of these experiments are described in this chapter. 
MATERIALS AND METHODS
Electrochemical deposition
PPy / Dex film was grown potentiostatically on the gold coated coverslips. A two electrode set up was used. The electrochemical cell was a 2 ml glass cuvette containing a working electrode (gold coated coverslip with or without the polymer-drug coatings) and a platinum counter electrode. The coating process was controlled using the Gamry Potentiostat, FAS2/Femostat (Gamry Instruments) with Gamry Framework software. The deposition solution (1 ml) contained 0.1 M pyrrole (Sigma) and 0.1 M dexamethasone disodium phosphate (Sigma). The actual electrode area immersed in the solution was ~0.77 cm 2 , which is the area covered by the resulting polymer-drug film. In the potentiostatic mode, a constant potential of 1.8 V relative to the counter was used. The amount of material deposited on the electrode surface was controlled by time via the total charge passed during deposition. A range of deposition charge densities (15 -120 mC/cm 2 ) were investigated. 25-30 mC/cm 2 was found to be optimal in terms of film stability and release efficiency, and was therefore selected for the rest of the study.
Fourier Transform Infra Red Spectroscopy (FTIR)
IR spectroscopic measurements were carried out using the Continnum IR microscope (ThermoNicolet). The detector was cooled with liquid nitrogen before use and the entire system was purged with in-house air at a flow rate of about 25 standard cubic feet per hour. The coated coverslips were placed on the microscope stage and the reflective IR spectrum was collected.
The samples were scanned 200 times in the range of 1000-4000 cm -1 . The spectrum of a clean gold coverslip was used as the background. The spectra were analyzed using the software OMNIC.
Ellipsometry
The 
RESULTS AND DISCUSSION
A one step electropolymerization was used to deposit films of PPy and Dex on the surface of gold coated electrodes. The underlying principle of electropolymerization of PPy is shown in figure 1 . In presence of a dopant A -(anions or negatively charged biomolecules or drugs), the monomers become electrically oxidized and polymerized and the resulting polymer gets deposited on the anode. Because the polymer backbone is positively charged, the anionic dopant molecule is incorporated to maintain charge neutrality. In our case the dopant was dexamethasone disodium phosphate (Dex), a synthetic glucocorticoid which acts as a pro-drug and can get converted into the active dexamethasone [41] . The chemical structure of the prodrug is shown in figure 2 . The presence of a phosphate group on the dexamethasone steroid ring structure imparts a negative charge to the drug, which can then be incorporated as a dopant in
PPy following electropolymerization.
The deposited film was characterized qualitatively by FTIR spectroscopy. The result is presented in figure 3 . From 1800 to 4000 cm -1 , the spectrum showed a continuous increase in absorption. This is the tail of the ~1 eV (~8066 cm -1 ) bipolaron absorption band, which is the signature for electrical conductivity of conducting polymers [42, 43] . The broad band around 1550 cm -1 is the characteristic absorption frequency for double bond vibration of the pyrrole ring [9, 37, 44, 45] . Proof of the presence of dexamethasone in the deposited film is clearly seen by the appearance of peaks at 3200-3500 cm -1 (hydroxyl), 2850-3000 cm -1 (methyl) and 1665-1760 cm -1 (carbonyl). These groups can be identified in the chemical structure of dexamethasone.
The thickness of the deposited film was detected using ellipsometry. The average thickness was found to be 50 nm for the films deposited at charge density of (~ 30 mC/cm 2 ).
The surface morphology of the PPy-Dex was revealed by tapping mode AFM as shown in figure   4 . For a deposition charge density of 30 mC/cm 2 , the films appear smooth. The root mean square roughness (RMS) value was 12 nm. Increasing the deposition charge density to about 120mC/cm 2 resulted in a drastic increase in surface roughness. The RMS value was measured to be about 95 nm. The films deposited at higher charge density did not appear to be uniform, with some areas being rougher or smoother than others.
CONCLUSION
PPy-Dex films were successfully grown on gold coated coverslips using electrochemical deposition techniques. The incorporation of the drug in the polymer films was confirmed by surface detection, of Dex in PPy-Dex films, using FTIR. The films were further characterized using ellipsometry and AFM analysis. 
DEXAMETHASONE RELEASE STUDIES
INTRODUCTION
The previous experiments established that dexamethasone was indeed deposited in the PPy-Dex films on the electrodes. The next logical step was to study the amount of dex released upon application of electrical stimuli. Cyclic voltammetry (CV) was the chosen type of stimuli, wherein the potential was swept between positive and negative values periodically. The film surface before and after release was analyzed by scanning electron microscopy (SEM) and optical microscopy. Impedance measurements were used to evaluate the electrical behavior of the film. The released drug was quantified using ultraviolet spectroscopy. The details of these experiments are described in this chapter.
MATERIALS AND METHODS
Scanning Electron Microscopy (SEM)
The PPy/Dex film surface morphology before and after drug release was studied under SEM. A JEOL 9335 Field Emission Gun SEM was used with a typical voltage of 10 kV. A thin film of gold/ palladium (3.5 nm) was sputtered onto the specimens using a Cressington Sputter Coater, before the surfaces were viewed.
Optical Microscopy
An optical microscope (Axioskope 2 MAT, Carl Zeiss) was employed to visualize the changes in morphology of the film after drug release. The images were taken using AxioCamMRC5
Camera (Carl Zeiss) attached to the scope. The images were taken and analyzed using AxioVision Rel 4.2 software.
Cyclic Voltammetry
Cyclic voltammetry (CV) was performed using Gamry Potentiostat, FAS2/Femostat (Gamry Instruments) under the software control of Gamry Framework For drug release studies, the CV was done in the two electrode cell described in 2.1.2 and the electrolyte was PBS (0.1 M, pH 7.2). The voltage was swept from -0.8 V to +1.4 V at a scan rate of 100 mV/s. Dex release was quantified by UV absorbance (detail see 2.5) after every five cycles till thirty cycles. Before beginning CV, the coated electrodes were soaked in distilled water to remove any loosely attached dexamethasone on the surface. This ensured that the release of Dex is caused mainly by the cyclic potential stimulus. A control was set up, in which the coated electrode was simply soaked in the PBS solution without electrical connection. UV reading of the solution was taken six successive times at time intervals of five minutes, to compare with the six sets of five CV cycles (5 CV cycle ~ 5 minutes at 100 mV/s). To study long term diffusion of Dex, if any, UV measurements were also taken after a 24-hour soaking.
Ultraviolet (UV) Spectroscopy
The released drug was detected using UV spectrometer (Genesys 5 TM spectrophotometer, Thermospectronic). The readings were taken at 242 nm, the characteristic absorbance band of Dex. Double distilled water was used as blank and the reading of PBS alone was subtracted from the reading for released sample. A standard calibration curve for Dex was plotted to define the quantitative relationship between observed absorbance and concentration of Dex.
Impedance Measurements
Electrochemical impedance spectroscopy was done using the Gamry Potentiostat, FAS2/Femostat, under the control of the Gamry Framework software. A solution of 0.1 M PBS buffer (25 ml) (pH = 7.2) was used as the electrolyte in a three-electrode cell. A platinum foil was used as the counter electrode, a saturated calomel electrode (SCE) was used as the reference electrode and the gold coated electrode with or without polymer coatings was used as the working electrode. AC sinusoid signal of 5 mV amplitude, with the DC potential set to 0 V was used as the input. The value of the impedance was determined at four discrete frequencies per decade over the range of 10 to 10 5 Hz.
Statistical Analysis
Statistical analysis was performed in SPSS. For comparisons involving multiple groups, ANOVA followed by Bonferroni's post-hoc analysis was used.
RESULTS AND DISCUSSION
The fundamental principle behind our drug release is explained as follows.
[ ( The release of Dex in solution was quantified using UV spectrometry at 242 nm. The released amount triggered by CV stimulus is displayed in figure 6 . It is evident from the graph that the release of Dex correlated in roughly linear fashion (R 2 = 0.9964) with the number of CV stimulus in the given CV cycle range. As a control, UV readings were taken from coated electrodes dipped in PBS to which no electrical stimulus was applied. As expected, there was no significant release of Dex from these control samples by diffusion. As diffusion is a time dependant process, we also took readings after 24 hours and saw no significant Dex release. The above observation indicates that our system is a true electrically controlled release system.
Estimates of the amount of drug deposited in the film were obtained using the following governing equation [46] 
where, Q dep is the deposition charge and Q cap is the charge capacity under 1 CV cycle.
For Q dep = 20 mC and Q cap = 2.5 mC, we can load nearly 17.4 µg/cm 2 of Dex in the PPy-Dex film. We are thus able to achieve 92% drug release at the end of 30 CV cycles.
Previous research has shown that dexamethasone is effective at a concentration of 0. µm [7, 48] . A release of 0.5 µg/cm 2 Dex will result in average Dex concentration of 1 µM within 500 µm radius from the electrode. Thus, 1 dose triggered by 1 CV may be sufficient to reduce the inflammation and with successive CV cycles the concentration of Dex remains in the µM range and can be expected to eliminate adverse tissue reaction to the electrode in long term.
Certainly, the in vivo situation may be different from our theoretical estimation. The actual efficiency and appropriate dosage of Dex will only be determined in the in vivo studies.
It should be pointed out that we also examined the UV absorption at 210 nm, the maximum UV absorbance band of pyrrole, and found that there was a minute amount of pyrrole monomer in the solution after the release. Fortunately, the contribution of pyrrole to the 242 nm absorbance, used for quantification of Dex, was negligible. The in vitro data also demonstrated that the leached pyrrole was not toxic to the cultured cells.
Most of the previously reported polypyrrole based molecule release systems utilize step potential stimuli (positive or negative depending on the charge of the ions to be released). The released dosage was found to be a function of time (time of applied potential stimuli). The step function was used initially in our preliminary studies, and was found to be less effective than cyclic potential stimuli towards drug release. The two release mechanisms will be analyzed and compared as follows.
In the case of step potential stimulation (for example with small anionic release), a negative potential reduces the polypyrrole, neutralizes the positive charge on the backbone and eliminates the electrostatic bonding between polypyrrole and its anionic dopants. The dissociation of the dopants from the polypyrrole chain may be an instant process, but the release of the anion is slow since it is driven by diffusion consisting of movement of anions from the inner film to the surface and from the surface to the solution. For dense films, as in our studies, the former is much slower, and hence the quick release is mainly from the surface, and the bulk release may take hours. In addition, under the applied negative potential, the reduced film will become electrically non-conductive. The longer the film is held at a negative potential, the more difficult it is to recover its conductivity after the stimulus is removed. Such a system is not ideal in most of the practical application when electrodes have other functions to perform.
In the case of cyclic potential stimulation, the film undergoes a fast swelling and deswelling process caused by ion and water movement in and out of the film [49] [50] [51] . This process may act as a pump to push the anions out and dramatically speed up the bulk release (seconds or minutes). When the potential is being swept at a high speeds (100 mV/sec, in our case), only a portion of the dopants are dissociated and pumped out during each cycle. This forms the basis of linear correlation between released dose and number of cyclic stimulus, ideal for on command dose controlled release. In addition, without application of a long potential bias, the polymer film can remain conductive after each release stimulus, consequently the electrode remains functional.
Several observations provide support for the above mechanism. First, a closer look at the deposited film surface before and after release was taken under SEM. Figure 7 shows that before release the film appears essentially smooth. After 50 CV cycles, however, there were appearance of cracks. This breakdown of the film starts to appear after ~30 CV cycles. This suggests that the polymer-drug film indeed undergoes physical changes of swelling and deswelling during the CV cycles which causes its delamination and breakdown. Also, higher charge density resulted in rougher films (shown in figure 4b ) but not higher drug release, which further provides evidence that the drug release triggered by the electrical stimulus (CV) occurs from within the film and was not a surface phenomenon.
The film morphology before and after CV stimulated release was also analyzed using optical microscopy, as shown in figure 8 . A change in color of the film induced by CV cycles was observed and it appeared to be darker in color than the original PPy-Dex film. The color of the film reflects its oxidative state and configuration of the polymer/dopants complex. This color change indicated that the film underwent structural and compositional changes during the course of CV treatment and the accompanying Dex release.
The electrical properties of the film were evaluated using impedance measurements.
Impedance is a complex quantity defined as Z (ω) ≡ |Z(ω)| e iθ(ω)
≡ v(ω) / i (ω), where v(ω) is the transform of an alternating potential signal applied to the system and i(ω) is the transform of the alternating current signal that results. The impedance is characterized by a magnitude (|Z|) and phase angle (θ), and is generally represented as a function of frequency. Impedance spectroscopy involves measuring the electrode impedance over a spectrum of frequencies.
Impedance spectroscopy is often used in neural electrode analysis for characterizing electrode/tissue or electrode/solution interface. So it is a relevant technique to be used here to examine the effect of deposited PPy/Dex on the bare electrode. The results are displayed in figure 9 . The impedance of the freshly made coated electrode is higher than the uncoated gold electrode at all frequencies. However, the impedance dropped immediately after the first few CV cycles. The impedance magnitude was lower than that of gold in the lower frequency range and it continued to be lower for the rest of the 30 CV cycles. It appears that the polymer-drug film is not as conductive initially, and perhaps was left at a reduced state immediately after , and Cl -from PBS, causing an increase in conductivity of the deposited film. Once in the more conductive state, the impedance becomes lower than bare gold, a commonly seen phenomenon in conducting polymer electrodes due to the higher surface area and more efficient charge transport of the polymer coating [52, 53] . This is important since having low impedance is beneficial in recording minute extracellular neural signals.
CONCLUSION
Dex release from PPy-Dex films on gold coated coverslips was carried out using CV technique.
A linear release profile was seen on application of successive CV cycles and we were able to successfully release 92% of the incorporated drug into PBS after 30 CV cycles. Surface characterization using SEM demonstrated that the polymer film starts to break down beyond 30 CV cycle. The optical microscopy images show change in color of the polymer film before and after drug release, indicating the structural and chemical changes in the film due to application of CV stimuli. Impedance studies also supported these observations, as indicated by lowered impedance after application of CV stimuli. Initial impedance of the film is very high. But after the first few CV cycles, the impedance drops at all frequencies and at the lower frequency range, the magnitudes are lower than those of the gold electrode. This implies deposited film was in its reduced state and needed 'rejuvenation', which was provided by initial CV cycles. The lowered impedance is maintained till 30 CV cycles.
4.0
IN VITRO CELL CULTURE STUDIES
INTRODUCTION
After the release profile of dexamethasone from PPy-Dex films on our gold electrodes was established, testing for the efficacy of released drug was the next step. For the in vitro studies, primary murine cerebellar cells were cultured using the techniques described in this chapter. The effect of released dexamethasone on both astrocytes and neurons was studied using immunohistochemistry and the analysis was done using optical microscopy and imaging.
MATERIALS AND METHODS
Primary neurons and astrocytes cell culture
Primary murine neuronal cultures were prepared as described by Schnitzer et al [39] . Briefly, following trypsinization and trituration, the cells were pelleted to remove debris and resuspended in DMEM with 10% horse serum (HyClone). These resuspended cells were plated on polylysine (Sigma; >400,000kD) coated glass coverslips (Fisher) at a cell density of 30,000 cells per 12mm diameter coverslip. Glial cultures were prepared using the protocol of Banker G and Goslin K [40] . Briefly, astrocyte and microglial cells were harvested, trypsinized, triturated and then plated using Dulbecco's modified eagle medium (DMEM), with 10% fatal calf serum (FCS) at 37 o C with 5% CO 2 , until confluent. These glial cultures were then trypsinized and replated on polylysine-coated coverslips. The cells were allowed to settle on the coverslips for 30 minutes and treated with three groups of media -control (DMEM + 10% FCS), Dex (DMEM +10% FCS + 10 -6 M Dex) and DexR (same as Dex, except that the Dex was released in PBS from the electrode coating and then added to the media at 10 -6 M concentration). Cells were kept in the incubator at 37° C and 5% CO 2 and analyzed on day 3 for astrocytes count. The neuronal cells were treated with control, Dex and DexR media and assayed for neuronal viability and growth on day 3.
Immunocytochemistry
Immunochemical labeling was done using antibodies against a neuronal marker, class III β-tubulin (Covance) and an astrocyte-specific marker, Glial Fibrillary Acid Protein (GFAP) (Dako). Cells were fixed with 4% paraformaldehyde for 10 minutes. In neuronal culture, cells were treated with 1% NP40 (CalBioChem) in 4% paraformaldehyde for 10 minutes at room temperature. Nonspecific binding was blocked by incubation with blocking buffer (0.5% bovine serum albumin and 10% horse serum in TBS). Primary and secondary antibodies were added for one hour each. Following immuno-staining cells were counterstained using the nuclear dye Hoechst 33258 (2 mg/ml in PBS) (Sigma). A similar protocol was followed for staining astrocytes.
Imaging and analysis
After immunostaining, digital images were taken using the fluorescence microscope (Axioskop 2 MAT, Carl Zeiss) using AxioCamMRC5 Camera (Carl Zeiss) attached to the scope and software AxioVision Rel 4.2. For neuronal cell culture, the neurite measurement feature of MetaMorph TM software was used. The software utilizes the values specified for various parameters i.e. cell body (width, minimum area, intensity above background), nuclei (minimum width, maximum width and intensity above background) and outgrowth (maximum width, intensity above background and minimum growth to log as significant) to accurately map the neurite outgrowth from fluorescent images. Healthy neurons were counted as those with at least one neurite and which showed co localization of β-tubulin and Hoescht stain. The cell counts on the astrocytes images was done manually by identifying GFAP staining co-localized with a Hoechst stained nuclei. For the neuronal culture, six coverslips were used for each condition (Ctrl, Dex, and DexR) and six images were taken for each coverslip at 20X magnification. For the astrocytes culture experiments, three coverslips were used for each condition and six images were taken for each coverslip at 10X magnification. In both cases the experiment was repeated twice.
Statistical analysis
Statistical analysis was performed in SPSS. For comparisons involving multiple groups (astrocytes count studies), ANOVA followed by Bonferroni's post-hoc analysis was used. For the neuronal cell culture experiment, n=6×2 and for the astrocytes culture, n=3×2. p values < 0.05 were considered as significant.
RESULTS AND DISCUSSION
To study the effect and efficacy of the released Dex, in vitro studies were conducted with primary murine cerebellar glial culture. Immunostaining with antibodies against GFAP revealed lowered number of reactive astrocytes in Dex treated samples when compared to those in control media on day 3 (figure 10a-c). In figure 10d , the day 3 astrocyte counts are represented after being normalized to the day 1 control. On day 3, the number of astrocytes in the control group almost doubled, while both the Dex added and Dex released groups showed significantly fewer astrocytes. In addition, there was no significant difference between the Dex added group and Dex released group, which implies that the released Dex was as effective as the added Dex From these studies we cannot determine if this is due to reduced proliferation or enhanced cell death.
Preliminary work with microglia cells also showed lowered growth of cells, as indicated in figure 11 . It is to be noted here that due to shortage of appropriate antibody for the microglia cells, the experiment with microglia cells could be done only once.
The released Dex may serve two purposes. Firstly, it decreases the number of reactive astrocytes. Astrocytes are a major component of the insulating glial sheath formed during the inflammatory response against the electrodes, when implanted in vivo. The objective therefore was to prevent them from getting into their reactive state and our in vitro data proves that the released Dex showed such effect.
Secondly, the drug shows a positive impact on neurons at this concentration as well. In vivo studies in mouse models have demonstrated that intraperitoneal injections of Dex may exert a neuroprotective effect towards injured neurons, but only in proper doses [54] . While higher doses of Dex may be toxic to neurons, a lower dose has proven to have a neuroprotective effect in those experiments. A similar mechanism may explain the higher neurite outgrowth seen in our experiments.
CONCLUSION
In vitro studies were successfully conducted to study the effect of released Dex on astro-glial cells and neurons. The drug was shown to maintain its anti-inflammatory properties, upon electrochemical release from the PPy-Dex films, as seen by lowered reactive astrocyte count.
Also, at the released concentration no toxic effect of Dex was seen on the cultured neurons, as indicated by healthy neuronal count. In-vitro cultured neurons were stained using β-tubulin and Hoescht dye. Scale bar is 50 µm. Co-localization of β-tubulin and Hoescht was used to identify neurons. Neurite measurement, using MetaMorph TM software, enabled identification of healthy neurons as those with at least one neurite. There is no significant difference between the three groups.
In this study, we have successfully developed a polypyrrole based electrode coating for electrically controlled and local delivery of an ionic form of dexamethasone (Dex), an antiinflammatory synthetic glucocorticoid. An appealing feature of the system is that it allows local drug release from individual electrode coatings in a controlled manner. Initial results show that out of a 50 nm thick PPy/Dex film, we are able to release 0.5 µg/cm 2 Dex after each CV cycle and upto 92% release after 30 CV cycles. In vitro studies on murine glial cells suggest that the released drug effectively reduces the number of reactive astrocytes and microglia. In addition, release of drug from the polymer coating does not produce any toxic side effects as seen by the healthy neuronal growth. In fact, the released drug caused increased neurite formation when compared to control.
In summary, we have established a drug delivery system that allows on-command, precise and local release of drugs from neural electrodes. The release dosage can be controlled via controlling the applied electrical stimuli. The mechanism is not confined to this particular polymer-drug system and may be extended to other combinations of conducting polymer and suitable dopants. Furthermore, this system can be easily integrated into any implantable electrode device setup, that are used clinically (such as deep brain stimulators and cochlear implants) or in a research setting (other neural prosthetic devices that are being actively developed). The electrical command for release control can be conducted via the preexisting circuits.
Further studies can be done to improve the system developed in this project. The current polymer polypyrrole allows consistent release for ~30 CV cycles, following which the film does not remain stable. While such a lifetime maybe sufficient in some applications, one may need to improve the stability of the polymer for prolonged release applications. This may be improved in the following ways. Firstly, an intrinsically more chemically and mechanically stable conducting polymer, like polyethylenedioxythiophene (PEDOT) can be selected. Secondly, the mechanical stability of the polymer and adherence between polymer and electrode substrate maybe enhanced. For example, addition of filler molecules or physical crosslinkers could stabilize the polymer film. To increase the adherence between the polymer and electrode substrate, modifications on the surface and in the original monomer can be done, which in turn help to form covalent binding between the polymer and electrode surface [55] . Alternatively the adherence can be improved by roughening the surface of the electrode [56] .
The next ideal step after in-vitro cell culture studies would be to study the release of the drug in vivo from implanted neural devices. While our CV and Dex release data suggests that most of the dex was incorporated as dopants and will not be released without electrical perturbance, we can not exclude the possible material degradation in vivo in long term which could lead to release without electrical command. This may be evaluated through in vivo degradation study.
Another aspect worth investigating would be how to increase drug load and the release efficiency. Research has shown [57, 58] that it is possible to electrochemically synthesize conducting polymers inside a hydrogel support matrix. Such a matrix offers the obvious advantages of higher water content and surface area due to 3D porous nature which allow more drug incorporation and faster release. Surface area can also be greatly enhanced by creating nano-fibrous morphology through various nano-templating techniques [59] [60] [61] .
